CR20210504A - Compuestos tricíclicos condensados útiles como agentes anticancerígenos - Google Patents

Compuestos tricíclicos condensados útiles como agentes anticancerígenos

Info

Publication number
CR20210504A
CR20210504A CR20210504A CR20210504A CR20210504A CR 20210504 A CR20210504 A CR 20210504A CR 20210504 A CR20210504 A CR 20210504A CR 20210504 A CR20210504 A CR 20210504A CR 20210504 A CR20210504 A CR 20210504A
Authority
CR
Costa Rica
Prior art keywords
compounds useful
anticancer agents
tricyclic compounds
fused tricyclic
relates
Prior art date
Application number
CR20210504A
Other languages
English (en)
Inventor
Iain Simpson
Kurt Gordon Pike
Doyle Joseph Cassar
Jason Grant Kettle
Christopher Phillips
Oliver Ross Steward
Scott Boyd
Michael Steven Bodnarchuk
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20210504A publication Critical patent/CR20210504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La memoria descriptiva se refiere a compuestos de Fórmula (A) y sales farmacéuticamente aceptables de los mismos. La memoria descriptiva también se refiere a procesos e intermedios utilizados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
CR20210504A 2019-03-05 2020-03-03 Compuestos tricíclicos condensados útiles como agentes anticancerígenos CR20210504A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813885P 2019-03-05 2019-03-05
US201962951146P 2019-12-20 2019-12-20
PCT/EP2020/055551 WO2020178282A1 (en) 2019-03-05 2020-03-03 Fused tricyclic compounds useful as anticancer agents

Publications (1)

Publication Number Publication Date
CR20210504A true CR20210504A (es) 2022-02-08

Family

ID=69740367

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210504A CR20210504A (es) 2019-03-05 2020-03-03 Compuestos tricíclicos condensados útiles como agentes anticancerígenos

Country Status (23)

Country Link
US (1) US20220204527A1 (es)
EP (1) EP3935060B1 (es)
JP (1) JP7453989B2 (es)
KR (1) KR20210135539A (es)
CN (1) CN113508118A (es)
AU (1) AU2020231045B2 (es)
BR (1) BR112021017408A2 (es)
CA (1) CA3131156A1 (es)
CL (1) CL2021002296A1 (es)
CO (1) CO2021012381A2 (es)
CR (1) CR20210504A (es)
DO (1) DOP2021000183A (es)
EC (1) ECSP21073246A (es)
IL (1) IL285761A (es)
JO (1) JOP20210241A1 (es)
MA (1) MA55198A (es)
MX (1) MX2021010674A (es)
PE (1) PE20220140A1 (es)
SG (1) SG11202109451TA (es)
TW (1) TW202100532A (es)
UY (1) UY38602A (es)
WO (1) WO2020178282A1 (es)
ZA (1) ZA202106192B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
EP4051678A1 (en) 2019-10-28 2022-09-07 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AU2020402701B2 (en) * 2019-12-11 2024-03-14 Eli Lilly And Company KRas G12C inhibitors
MX2022007515A (es) 2019-12-20 2022-09-19 Mirati Therapeutics Inc Inhibidores de sos1.
TWI799871B (zh) * 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
AU2021293228A1 (en) 2020-06-18 2023-02-09 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
CN114539286B (zh) * 2020-11-24 2024-02-02 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
TW202235082A (zh) 2020-12-04 2022-09-16 美商美國禮來大藥廠 Ｋｒａｓ ｇ１２ｃ抑制劑
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
JP2024513881A (ja) * 2021-04-08 2024-03-27 ジェネンテック， インコーポレイテッド オキサゼピン化合物及びがんの治療におけるその使用
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AU2022371727A1 (en) 2021-10-22 2024-05-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
TW202325298A (zh) * 2021-11-01 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
WO2023126822A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
WO2023168036A1 (en) 2022-03-04 2023-09-07 Eli Lilly And Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318412A1 (en) * 2006-07-11 2009-12-24 Takahiro Matsumoto Tricyclic heterocyclic compound and use thereof
NO2714752T3 (es) * 2014-05-08 2018-04-21
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AR111776A1 (es) 2017-05-11 2019-08-21 Astrazeneca Ab Heteroarilos inhibidores de las proteínas ras mutantes de g12c
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
EP3935060A1 (en) 2022-01-12
US20220204527A1 (en) 2022-06-30
ECSP21073246A (es) 2021-11-30
BR112021017408A2 (pt) 2022-01-18
JOP20210241A1 (ar) 2023-01-30
PE20220140A1 (es) 2022-01-27
SG11202109451TA (en) 2021-09-29
TW202100532A (zh) 2021-01-01
CN113508118A (zh) 2021-10-15
CO2021012381A2 (es) 2021-10-20
MX2021010674A (es) 2021-09-28
MA55198A (fr) 2022-01-12
WO2020178282A1 (en) 2020-09-10
CA3131156A1 (en) 2020-09-10
EP3935060B1 (en) 2023-11-15
CL2021002296A1 (es) 2022-04-29
EP3935060C0 (en) 2023-11-15
AU2020231045A1 (en) 2021-10-28
ZA202106192B (en) 2022-08-31
IL285761A (en) 2021-10-31
DOP2021000183A (es) 2021-09-30
KR20210135539A (ko) 2021-11-15
UY38602A (es) 2020-09-30
JP2022523981A (ja) 2022-04-27
JP7453989B2 (ja) 2024-03-21
AU2020231045B2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
PH12019501724A1 (en) Estrogen receptor modulators
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
TW201613864A (en) Novel compounds
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
MX2016010745A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina.
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
MX2021015727A (es) Derivados de piridin-3-ilo.
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
EA202192366A1 (ru) Конденсированные трициклические соединения, применимые в качестве противораковых средств
EA202092600A1 (ru) Тетрациклические гетероарильные соединения
EA201991734A1 (ru) Модуляторы рецептора эстрогена